Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
Clinical trial NCT04091126 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04091126
- Sponsor
- GlaxoSmithKline
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-18
- Primary completion
- 2025-06-02
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.